Hearing Therapy Pioneer Auris Medical Gets $50 Million Series C Financing
This article was originally published in The Pink Sheet Daily
Executive Summary
Auris Medical AG has completed Europe’s largest biotech investing round so far this year, led by Sofinnova Partners and Sofinnova Ventures, and hopes to advance the development of new otologic drugs for hearing dysfunction.
You may also be interested in...
With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders
The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.
Financings Of The Fortnight Looks To The High-Tech Sector For New Life-Science Capital Sources
Plus news on recent financings by Elcelyx, Jounce Therapeutics, Retrophin and e-Therapeutics.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.